Shots:

• The US FDA has issued a EUA to Gilead for emergency use of remdesivir to treat hospitalized COVID-19 patients. In May- Gilead has extended a voluntary non-exclusive license to Cipla to manufacture and market Cipla’s Remedisvir called CIPREMI
• Cipla has received DCGI’s approval for restricted emergency use in India as part of the accelerated approval process. Cipla will provide training on the use of the drug- informed patient consent documents- conduct post-marketing surveillance as well as to conduct a P-IV clinical trial on Indian patients
• As per ACTT-1 study- 1063 patients were treated with Remdesivir vs PBO over 60 centers across the US- EU and Asia demonstrated faster time to clinical recovery in hospitalized patients with the mortality rate as (7.1% vs 11.9%)

Click here to read full press release/ article | Ref: Cipla | Image: India TV News